Exicure, Inc. (XCUR): Price and Financial Metrics

Exicure, Inc. (XCUR): $0.37

0.03 (-7.50%)

POWR Rating

Component Grades








Add XCUR to Watchlist
Sign Up

Industry: Biotech




#81 of 383

in industry

XCUR Price/Volume Stats

Current price $0.37 52-week high $1.78
Prev. close $0.40 52-week low $0.37
Day low $0.37 Volume 28,900
Day high $0.43 Avg. volume 28,212
50-day MA $0.62 Dividend yield N/A
200-day MA $0.91 Market Cap 3.20M

XCUR Stock Price Chart Interactive Chart >

XCUR Stock Summary

  • With a market capitalization of $4,064,704, EXICURE INC has a greater market value than just 2.17% of US stocks.
  • XCUR's current price/earnings ratio is 1.33, which is higher than only 0.71% of US stocks with positive earnings.
  • Revenue growth over the past 12 months for EXICURE INC comes in at 584.21%, a number that bests 98.66% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to XCUR, based on their financial statements, market capitalization, and price volatility, are ACLS, CMBM, SCKT, GPRO, and HYPR.
  • Visit XCUR's SEC page to see the company's official filings. To visit the company's web site, go to www.exicuretx.com.

XCUR Valuation Summary

  • XCUR's EV/EBIT ratio is 2.7; this is 78.74% lower than that of the median Healthcare stock.
  • XCUR's price/sales ratio has moved down 12.4 over the prior 67 months.

Below are key valuation metrics over time for XCUR.

Stock Date P/S P/B P/E EV/EBIT
XCUR 2023-11-20 0.2 0.5 1.6 2.7
XCUR 2023-11-17 0.2 0.5 1.7 2.8
XCUR 2023-11-16 0.2 0.5 1.6 2.7
XCUR 2023-11-15 0.2 0.5 1.6 2.7
XCUR 2023-11-14 0.2 0.5 1.6 2.7
XCUR 2023-11-13 0.2 0.5 1.7 2.8

XCUR's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • XCUR has a Quality Grade of C, ranking ahead of 38.19% of graded US stocks.
  • XCUR's asset turnover comes in at 0.039 -- ranking 338th of 682 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows XCUR's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.039 1 -0.674
2021-03-31 0.085 1 -0.500
2020-12-31 0.161 1 -0.327
2020-09-30 0.157 1 -0.336
2020-06-30 0.152 1 -0.444
2020-03-31 0.133 1 -0.757

XCUR Price Target

For more insight on analysts targets of XCUR, see our XCUR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $10.00 Average Broker Recommendation 1.38 (Strong Buy)

Exicure, Inc. (XCUR) Company Bio

Exicure, Inc. operates as a clinical stage bio-technology company. The Company develops a new class of immunomodulatory and gene regulating drugs against validated targets, as well as addresses diseases such as oncology, immunology, and dermatology. Exicure serves customers in the United States.

XCUR Latest News Stream

Event/Time News Detail
Loading, please wait...

XCUR Latest Social Stream

Loading social stream, please wait...

View Full XCUR Social Stream

Latest XCUR News From Around the Web

Below are the latest news stories about EXICURE INC that investors may wish to consider to help them evaluate XCUR as an investment opportunity.

Lacklustre Performance Is Driving Exicure, Inc.'s (NASDAQ:XCUR) 25% Price Drop

Exicure, Inc. ( NASDAQ:XCUR ) shares have had a horrible month, losing 25% after a relatively good period beforehand...

Yahoo | August 29, 2023

Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors

CHICAGO, August 23, 2023--Exicure, Inc. announces appointment of new CEO and CFO and changes to Board of Directors.

Yahoo | August 23, 2023

Exicure First Half 2023 Earnings: US$1.38 loss per share (vs US$3.71 loss in 1H 2022)

Exicure ( NASDAQ:XCUR ) First Half 2023 Results Key Financial Results Net loss: US$10.2m (loss narrowed by 36% from 1H...

Yahoo | August 15, 2023

Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update

CHICAGO, August 11, 2023--Exicure, Inc. reports second quarter 2023 financial results and provides corporate update.

Yahoo | August 11, 2023

Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update

CHICAGO, July 14, 2023--Exicure, Inc. reports first quarter 2023 financial results and provides corporate update.

Yahoo | July 14, 2023

Read More 'XCUR' Stories Here

XCUR Price Returns

1-mo -39.36%
3-mo -55.43%
6-mo -61.05%
1-year -63.37%
3-year -99.18%
5-year -99.66%
YTD -67.83%
2022 -81.03%
2021 -88.58%
2020 -38.11%
2019 -19.21%
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!